InvestmentJun 29, 2026, 08:46 AM
Akari Therapeutics Completes PIPE, Raises $8.3M in Q2 2026
AI Summary
Akari Therapeutics, Plc announced the completion of its previously announced PIPE, consolidating the remaining scheduled investment closings into a single funding event. Combined with warrant exercises completed in May 2026, the company received approximately $8.3 million in total capital during Q2 2026. This additional capital is expected to provide financial flexibility to advance AKTX-101 towards a Phase 1 first-in-human clinical trial and pursue strategic partnerships for its proprietary PH1 RNA splicing modulator ADC payload.
Key Highlights
- Akari Therapeutics completed its previously announced PIPE, consolidating remaining investment closings into a single funding event.
- The company received approximately $8.3 million in total capital during Q2 2026, including warrant exercises.
- The PIPE involved $5.5 million in gross proceeds, initially planned for three tranches.
- The second and third PIPE closings were consolidated and occurred on June 26, 2026.
- Approximately $2.8 million in additional proceeds came from warrant exercises in May 2026.
- The issuance of Series H, I, and J warrants is subject to shareholder approval at the AGM on June 30, 2026.
- The capital provides financial flexibility to advance AKTX-101 towards a Phase 1 clinical trial.
Price Impact
More from AKTX